The highest profile medtech news out of this year's European Society of Cardiology Congress was the presentation of the MITRA-FR results, which cast doubt on the benefits of treating severe secondary mitral valve regurgitation with Abbott Vascular's MitraClip. (Also see "ESC Congress 2018: MITRA-FR Finds No Benefit Of MitraClip In Severe Secondary MR" - Medtech Insight, 31 August, 2018.) But the Munich meeting also featured several other noteworthy device-trial presentations. Here's a look at a few of them.
Results of the CRYO4PERSISTENT AF clinical trial show treatment of atrial fibrillation with Medtronic PLC's Arctic Front Advance Cryoballoon pulmonary-vein isolation ablation balloon catheter improves patients' quality of...